Bcl2 is the target of Venetoclax26 (Drug-2) (Supplementary Fig. 1a, b), a BH3 chemical mimetic that blocks the anti-apoptotic Bcl2 protein and is clinically-approved for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) treatment21. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.